TY - JOUR
T1 - Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV
AU - Greenberg, Lauren
AU - Ryom, Lene
AU - Bakowska, Elzbieta
AU - Wit, Ferdinand
AU - Bucher, Heiner C.
AU - Braun, Dominique L.
AU - Phillips, Andrew
AU - Sabin, Caroline
AU - d’Arminio Monforte, Antonella
AU - Zangerle, Robert
AU - Smith, Colette
AU - de Wit, Stéphane
AU - Bonnet, Fabrice
AU - Pradier, Christian
AU - Mussini, Cristina
AU - Muccini, Camilla
AU - Vehreschild, J. rg J.
AU - Hoy, Jennifer
AU - Svedhem, Veronica
AU - Miró, Jose M.
AU - Wasmuth, Jan-Christian
AU - Reiss, Peter
AU - Llibre, Josep M.
AU - Chkhartishvili, Nikoloz
AU - Stephan, Christoph
AU - Hatleberg, Camilla I.
AU - Neesgaard, Bastian
AU - Peters, Lars
AU - Jaschinski, Nadine
AU - Dedes, Nikos
AU - Kuzovatova, Elena
AU - van der Valk, Marc
AU - Menozzi, Marianna
AU - Lehmann, Clara
AU - Petoumenos, Kathy
AU - Garges, Harmony
AU - Rooney, Jim
AU - on behalf of the RESPOND and D:A:D Study Groups
AU - Young, Lital
AU - Lundgren, Jens D.
AU - Bansi-Matharu, Loveleen
AU - Mocroft, Amanda
N1 - Funding Information: J.M.M. has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work. C.L. has received honoraria for speaking at educational events or consulting from BioNTech, Pfizer, Astra Zeneca, MSD, Novartis, Gilead, Janssen and ViiV. J.R. is an employee and stockholder of Gilead Sciences. A.M. has received honoraria, travel support and lecture fees from ViiV and Gilead, and honoraria from Eiland and Bonnin, all outside the submitted work. Publisher Copyright: © 2023 by the authors.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.
AB - Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.
KW - AIDS defining cancer
KW - HIV
KW - body mass index
KW - incidence
KW - infection
KW - non-AIDS defining cancer
KW - smoking
KW - trends
UR - http://www.scopus.com/inward/record.url?scp=85166264576&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers15143640
DO - https://doi.org/10.3390/cancers15143640
M3 - Article
C2 - 37509301
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 14
M1 - 3640
ER -